Table 5. Veliparib as monotherapy.
Clinical trial | Phase | Study objective | Germline mutations | Somatic mutations | Outcomes |
Veliparib monotherapy | |||||
NCT00892736 [43] | I | Refractory BRCA1/2-mutated solid cancer; platinum-refractory ovarian, fallopian tube, or primary peritoneal cancer; or basal-like breast cancer | Refractory BRCA1/2-mutated solid cancer | BRCA-positive patients had about a 58% response rate. Pancreatic data are limited |